Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine Expanded Access for AML and MDS Patients
NCT00760084Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2005
- Primary completion
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Eisai Co., Ltd.. Started Jul 2005; status: completed.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00760084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00760084.